Hospital
Hospital Service District No. 1 of the Parish of ST. Mary
Hospital Service District No. 1 of the Parish of ST. Mary was paid $12.38M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is 99283, emergency room visit (moderate) — 47% of everything it billed.
33Billing provider infoHOSPITAL SERVICE DISTRICT NO. 1 OF THE PARISH OF ST. MARY
FRANKLIN, LA 70538
FRANKLIN, LA 70538
33aNPI1043218365assigned 07/11/2005
33bProvider typeRural Acute Care Hospital
28Total paid$12.38M
24GClaims167,962
24DCodes billed84
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Louisiana
Rank by total paid#5 of 8
Median peer was paid$12.38M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,313 | $1.22M | |
| 2019 | 19,562 | $1.32M | |
| 2020 | 14,331 | $779K | |
| 2021 | 26,830 | $1.78M | |
| 2022 | 30,206 | $2.29M | |
| 2023 | 34,477 | $2.79M | |
| 2024incomplete | 24,243 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 47% | 23,380 | 21,062 | $5.77M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 8,446 | 7,665 | $2.29M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 9,164 | 8,439 | $1.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.9% | 3,663 | 3,231 | $984K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.3% | 10,789 | 8,964 | $530K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 2,857 | 2,443 | $192K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 4,831 | 4,436 | $168K |
| 80053 | Comprehensive metabolic panel | <1% | 16,144 | 14,213 | $117K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,900 | 1,406 | $105K |
| 80061 | Lipid panel | <1% | 5,019 | 4,685 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,819 | 21,604 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 829 | 601 | $50K |
72 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,466 | $50K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,354 | $49K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,786 | $39K |
| 74018 | <1% | 266 | $39K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 210 | $39K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,687 | $36K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 29 | $36K |
| 71045 | Radiologic examination, chest; single view | <1% | 738 | $30K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 90 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 258 | $24K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,776 | $23K |
| 85027 | <1% | 4,911 | $22K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 176 | $20K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,145 | $17K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 90 | $17K |
| 81001 | <1% | 7,885 | $16K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 20 | $14K |
| 87081 | <1% | 2,068 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 267 | $11K |
| 0240U | <1% | 67 | $9K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 89 | $9K |
| 80050 | General health panel | <1% | 231 | $8K |
| 84484 | <1% | 1,188 | $8K | |
| 83880 | <1% | 384 | $8K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 371 | $7K |
| 81025 | <1% | 932 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 730 | $6K |
| 82553 | <1% | 1,042 | $6K | |
| 74019 | <1% | 70 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 46 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 29 | $5K |
| 82550 | <1% | 1,175 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 514 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 31 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 323 | $2K |
| 83735 | <1% | 497 | $2K | |
| 83690 | <1% | 396 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 67 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 99 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 756 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 31 | $1K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 31 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 51 | $912.43 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 174 | $866.10 |
| 85610 | <1% | 321 | $736.49 | |
| 82150 | <1% | 134 | $576.74 | |
| 85730 | <1% | 165 | $543.82 | |
| 83550 | <1% | 66 | $499.35 | |
| 83540 | <1% | 66 | $369.65 | |
| 86140 | <1% | 92 | $340.66 | |
| 84100 | <1% | 132 | $327.06 | |
| 82670 | <1% | 13 | $307.34 | |
| A9270 | Non-covered item or service | <1% | 1,989 | $171.23 |
| 82607 | <1% | 13 | $165.88 | |
| 82746 | <1% | 13 | $161.70 | |
| J2704 | Injection, propofol, 10 mg | <1% | 907 | $159.23 |
| J1094 | Injection, dexamethasone acetate, 1 mg | <1% | 130 | $158.11 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 36 | $155.03 |
| 82728 | <1% | 13 | $149.93 | |
| 84480 | <1% | 15 | $130.95 | |
| 85379 | <1% | 15 | $101.80 | |
| 84436 | <1% | 15 | $92.12 | |
| 87088 | <1% | 16 | $84.04 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 36 | $62.38 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 26 | $58.25 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 18 | $56.79 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $52.43 |
| 81003 | <1% | 13 | $18.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 141 | $11.69 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 15 | $10.74 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 105 | $5.01 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 57 | $0.13 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUIDRY, STEPHANIE (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Hospital Service District No. 1 of the Parish of ST. Mary | Franklin, LA | $1.25M |
| Hospital Service District No. 1 of the Parish of ST. Mary | Franklin, LA | $60K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.